BioInsights - New horizons in cellular immunotherapy: next-gen platforms and modalities

New horizons in cellular immunotherapy: next-gen platforms and modalities

Guest Editor:

David Morrow, Scientific Programme Manager, Translational Medicine & Drug Development at EATRIS

October 2020

Download full spotlight

Temferon™, an ex-vivo genetically modified cell therapy aiming to fill the gaps for solid tumor immunotherapy

S Mazzoleni,

B Gentner,

V Brambilla et al.

13 November 2020

Expert Insight

Read more
Evolving the role of gene editing in cell therapy

J Frampton,

T Meissner,

T Thwaites

29 October 2020

Innovator Insight

Read more
Promising non-viral vector for efficient and versatile delivery of mRNA for antigen-specific immunotherapy

R Firdessa-Fite,

J Postigo-Fernandez,

V Toussaint-Moreau et al.

29 October 2020

Innovator Insight

Read more
The progression & delivery of adoptive cellular immune therapies: leveraging single-cell resolution & novel algorithms to overcome the challenges associated with allogeneic & autologous immune cell therapies

V Moignard,

A De Riva,

R Elgueta

29 October 2020

Innovator Insight

Read more
Engineering precision cell therapy for immune-mediated disease

M Milone,

G Binder

27 October 2020

Expert Insight

Read more
FDA perspective on the preclinical development of cell-based immunotherapies

A Kosmides Galaro,

C Saeui

23 October 2020

Regulatory Insight

Read more
Driving lupus out with CARs

M Radic

22 October 2020

Interview

Read more
Developing harmonized immune platforms: a must-have for realizing personalized therapies in solid tumors

D Morrow,

J Langermans,

A Ussi et al.

20 October 2020

Commentary

Read more
From a clinician’s perspective: road to safer CAR-T cell immunotherapies

C Li,

H Mei

20 October 2020

Expert Insight

Read more
Immunological tolerance: scanning a barren landscape for signs of sustained growth

H Petropoulos,

T Davies,

P Fairchild

28 September 2020

Expert Insight

Read more
Is a second wave of (CAR T) cell based cancer therapies a mirage or reality?

D Gilham

22 September 2020

Commentary

Read more
Evolving the role of gene editing in cell therapy

Jonathan Frampton, Horizon Discovery at Horizon Discovery

Tristan Thwaites, Lead Technical Scientist at Cell and Gene Therapy Catapult

Torsten Meissner, Postdoctoral Fellow, Department of Stem Cell & Regenerative Biology at Harvard Medical School

6 October 2020

Webinar

Watch now

CELL & GENE THERAPY INSIGHTS

New horizons in cellular immunotherapy: next-gen platforms and modalities

Temferon™, an ex-vivo genetically modified cell therapy aiming to fill the gaps for solid tumor immunotherapy

Evolving the role of gene editing in cell therapy

Promising non-viral vector for efficient and versatile delivery of mRNA for antigen-specific immunotherapy

The progression & delivery of adoptive cellular immune therapies: leveraging single-cell resolution & novel algorithms to overcome the challenges associated with allogeneic & autologous immune cell therapies

Engineering precision cell therapy for immune-mediated disease

FDA perspective on the preclinical development of cell-based immunotherapies

Driving lupus out with CARs

Developing harmonized immune platforms: a must-have for realizing personalized therapies in solid tumors

From a clinician’s perspective: road to safer CAR-T cell immunotherapies

Immunological tolerance: scanning a barren landscape for signs of sustained growth

Is a second wave of (CAR T) cell based cancer therapies a mirage or reality?

Evolving the role of gene editing in cell therapy

CELL & GENE THERAPY INSIGHTS

New horizons in cellular immunotherapy: next-gen platforms and modalities

Sponsor

Temferon™, an ex-vivo genetically modified cell therapy aiming to fill the gaps for solid tumor immunotherapy

Evolving the role of gene editing in cell therapy

Promising non-viral vector for efficient and versatile delivery of mRNA for antigen-specific immunotherapy

The progression & delivery of adoptive cellular immune therapies: leveraging single-cell resolution & novel algorithms to overcome the challenges associated with allogeneic & autologous immune cell therapies

Engineering precision cell therapy for immune-mediated disease

FDA perspective on the preclinical development of cell-based immunotherapies

Driving lupus out with CARs

Developing harmonized immune platforms: a must-have for realizing personalized therapies in solid tumors

From a clinician’s perspective: road to safer CAR-T cell immunotherapies

Immunological tolerance: scanning a barren landscape for signs of sustained growth

Is a second wave of (CAR T) cell based cancer therapies a mirage or reality?

Evolving the role of gene editing in cell therapy